Kite Pharma (KITE) Post Smaller Q2 Loss on Higher Revs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/20/2026
- Wall Street indexes fall, with Iran and earnings season in focus
- Oil settles 1% higher as hopes of renewed US-Iran negotiations offset Houthi threat
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
Kite Pharma (KITE) PT Raised to $120 at Canaccord Genuity
August 8, 2017 12:51 PM EDTCanaccord Genuity raised its price target on Kite Pharma (NASDAQ: KITE) to $120.00 (from $115.00) while maintaining a Buy rating.
Analyst John Newman with the coverage.
... More